areas of unmet need for dlbcl: primary refractory disease and double-hit lymphoma
Published 2 years ago • 323 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
1:34
the standard of care for dlbcl and double-hit lymphoma
-
0:43
the unmet need in dlbcl
-
1:16
unmet needs in second-line dlbcl and challenges in this space
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
0:57
outcomes of patients with double-hit lymphoma treated with car-t therapy
-
2:32
unmet needs in t-cell lymphoma and the importance of better understanding disease biology
-
1:19
contemporary approaches to the management of r/r dlbcl
-
47:23
primary central nervous system lymphoma
-
11:17
car-t cells: engineered cancer killers
-
19:23
lymphoma explained clearly - hodgkins & non-hodgkin's pathophysiology
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
2:28
treatment approaches for patients with r/r dlbcl: uk perspective
-
1:45
improving the frontline treatment of dlbcl
-
3:59
current research on diffuse large b-cell lymphoma (dlbcl)
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
7:08
unmet needs and therapeutic targets for diffuse large b-cell lymphoma and follicular lymphoma
-
3:04
future directions for the treatment of diffuse large b-cell lymphoma
-
1:30
phase ib/iia study of azd4573 and acalabrutinib in patients with r/r dlbcl
-
11:07
diffuse large b cell lymphoma front line management dr chan cheah, consultant haematologist, sir c
-
3:09
redlamp 4: circulating tumor dna & ct monitoring for untreated dlbcl - a correlative biomarker study
-
14:40
update on the clinical management of diffuse large b-cell lymphoma
-
2:06
car-t therapy vs autologous transplantation in r/r dlbcl